Holen Sie sich die Stockscreener-App
12.56
0.18%
-0.0362
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt RDY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$12.60
Offen:
$12.67
24-Stunden-Volumen:
338.71K
Relative Volume:
0.13
Marktkapitalisierung:
$10.46B
Einnahmen:
$3.81B
Nettoeinkommen (Verlust:
$485.75M
KGV:
21.39
EPS:
0.5873
Netto-Cashflow:
$175.50M
1W Leistung:
-2.65%
1M Leistung:
-5.36%
6M Leistung:
-2.80%
1J Leistung:
-13.14%
1-Tages-Spanne:
$12.54
$12.74
1-Wochen-Bereich:
$12.54
$12.95
52-Wochen-Spanne:
$12.19
$15.67
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Compare RDY vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
12.56 | 10.49B | 3.81B | 485.75M | 175.50M | 0.5873 |
TAK
Takeda Pharmaceutical Co Adr
|
17.02 | 54.77B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.10 | 44.48B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.54 | 37.30B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.73 | 32.10B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
532.85 | 22.74B | 3.17B | 1.29B | 1.01B | 27.09 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-23 | Herabstufung | Goldman | Neutral → Sell |
| 2025-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-12-19 | Herabstufung | Nomura | Buy → Neutral |
| 2024-01-11 | Herabstufung | Jefferies | Buy → Underperform |
| 2023-08-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-05-18 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-30 | Eingeleitet | JP Morgan | Underweight |
| 2022-11-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | Fortgesetzt | BofA Securities | Neutral |
| 2021-07-27 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-09-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-09-18 | Hochstufung | Investec | Sell → Hold |
| 2020-01-28 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-27 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-09 | Hochstufung | Citigroup | Sell → Buy |
| 2019-11-04 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | Hochstufung | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | Hochstufung | Macquarie | Neutral → Outperform |
| 2019-06-20 | Eingeleitet | Deutsche Bank | Hold |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | Hochstufung | CLSA | Outperform → Buy |
| 2019-01-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2017-09-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | Hochstufung | CLSA | Underperform → Outperform |
| 2017-07-28 | Herabstufung | CLSA | Underperform → Sell |
| 2016-07-27 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2016-07-27 | Herabstufung | Jefferies | Hold → Underperform |
| 2016-02-10 | Hochstufung | Credit Agricole | Underperform → Buy |
| 2015-11-10 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Dr Reddys Laboratories Ltd Adr Aktie (RDY) Neueste Nachrichten
Price to earnings forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView
Korea’s SK Hynix makes history in US – raises $26.5 billion in largest foreign debut - financialexpress.com
SK Hynix plans to price its US listing at $149 - financialexpress.com
Dr Reddy's Shares Slide Over 6% After Semaglutide Batch Quality Concern - NDTV Profit
Dr. Reddy's Labs ADR highlights its global generics footprint as investors track U.S. healthcare dem - ad-hoc-news.de
Dr. Reddy's Labs ADR highlights global generics reach. Investors look at U.S. listing context - ad-hoc-news.de
RDY News | DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - ChartMill
Full Transcript: Dr Reddy's Laboratories Q4 2026 Earnings Call - Sahm
Eli Lilly Upgraded, Carvana Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dr. Reddy’s Laboratories files FY26 annual report with US SEC - scanx.trade
RDDA Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView
Enterprise value to EBITDA forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView
Dr. Reddy's Labs ADR files Form 20-F, shares stay tied to US pharma peers - AD HOC NEWS
Enterprise value to EBIT forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView
Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR - TradingView
Dr. Reddy’s files 2026 annual report with the SEC - Stock Titan
659157 Forecast — Price Target — Prediction for 2027 - TradingView
Form 6K DR REDDYS LABORATORIES LTD For: 22 June By Investing.com - Investing.com Nigeria
Form 6K Kinross Gold Corp For: 22 June By Investing.com - Investing.com Nigeria
Dr. Reddy’s (NYSE: RDY) allots 6,730 ESOP shares to employees - Stock Titan
Why Dr. Reddy's Venlafaxine XR capsules quietly matter for everyday patients - ad-hoc-news.de
Dr. Reddy’s Allots 6,730 ESOP Shares, Expands Issued Capital - TipRanks
Why Dr. Reddy’s Celevida Maxx matters for Indian diabetics - AD HOC NEWS
NIFTY50, SENSEX today: Wall Street cues, FII activity, key things to know before markets open on June 19 - Upstox
Dr. Reddy's Labs (ADR) Stock (US2565981035): Earnings and valuation keep the ADR in focus - ad-hoc-news.de
Dr. Reddy's Laboratories Ltd Stock (INE089A01023): U.S. Bosutinib Launch And Pre-market Drop Put ADR - Ad-hoc-news.de
Dr. Reddy's Laboratories stock (INE089A01023): focus on recent FDA progress and US generics growth - Ad-hoc-news.de
[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.
With Lenalidomide Headwinds Behind, Dr. Reddy's Turns to Biosimilars and Consumer Health for Growth - Morningstar
Dr. Reddy’s (NYSE: RDY) allots 12,100 ESOP shares, updates capital - Stock Titan
Dr. Reddy’s Laboratories issues 12,100 equity shares under stock options scheme - Business Upturn
Topicus submits revised $2.00 per share proposal for ReadyTech By Investing.com - Investing.com UK
Topicus submits revised $2.00 per share proposal for ReadyTech - Investing.com UK
RDY - Finviz
Dr. Reddy's Laboratories Ltd ADR (RDY-N) Stock Price and News - The Globe and Mail
Generic Ozempic to hit pharmacies this week, but availability will vary across Canada - The Globe and Mail
Earnings call transcript: Dr. Reddy’s Q4 2026 misses earnings expectations - Investing.com UK
Earnings call transcript: Dr. Reddy’s Q4 2026 misses earnings expectations By Investing.com - Investing.com India
Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push - Sahm
Dr. Reddy's Laboratories Ltd stock (INE089A01023): earnings miss and dual-market focus draw attentio - AD HOC NEWS
Dr. Reddy's Laboratories stock: Earnings miss shapes outlook - Ad-hoc-news.de
8 Stocks To Buy For Long Term: Analysts recommend 3 largecap, 3 midcap, 2 smallcap scrips; Dr Reddy's Labs on the list - Zee Business
Dr. Reddy’s Labs ADR earnings missed by $0.05, revenue fell short of estimates - Investing.com India
Dr. Reddy's Earnings: Lenalidomide's Slide Digs Into Numbers, but Base Business Remains Solid - Morningstar
Earnings call transcript: Dr. Reddy’s Q4 2026 revenue misses forecast - Investing.com
Earnings call transcript: Dr. Reddy’s Q4 2026 revenue misses forecast By Investing.com - Investing.com Australia
Dr. Reddy's Laboratories Ltd stock (INE089A01023): Board meeting set for Q4 FY26 results - AD HOC NEWS
Finanzdaten der Dr Reddys Laboratories Ltd Adr-Aktie (RDY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.53%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):